

30 October 2008



**Plant Health Care plc
("Plant Health Care" or "the Company")**

NEW BOARD APPOINTMENTS

Plant Health Care (AIM: PHC.L), a leading provider of natural products to the agriculture and landscape industries, announces that David Buckeridge and Jeremy Scudamore have been appointed to its Board as non-executive directors, with immediate effect.

Dr. David Buckeridge, PhD, Plant Sciences, 48, is currently non-executive director of Archimica BV (Netherlands), Oxitec Ltd and NLA FP Limited.

Dr. Buckeridge spent 20 years with multinational pharmaceutical company AstraZeneca, where he obtained significant experience in the pharmaceutical, genomics and chemical industries, with a particular emphasis on agribusiness. Dr. Buckeridge held a number of senior positions during his time at AstraZeneca, including five years spent running the company's commercial seed business in the United States. In 1999, he was appointed as a main board director of AstraZeneca's seeds business and then CEO of Advanta, then the largest independent agronomic seeds business in the world.

Jeremy Scudamore, 61, is currently non-executive chairman of SkyePharma PLC, Oxford Advanced Surfaces PLC and Boardlink Group Limited. Mr Scudamore is also a non-executive director of ARM Holdings PLC and Oxford Catalysts Group PLC.

Mr. Scudamore worked for 35 years in the life science, agrochemical and specialty chemical businesses of ICI, AstraZeneca and Avecia, latterly as chief executive officer and chairman of the Avecia Group. Previously chief executive officer of Zeneca Specialties, Mr Scudamore led the £1.3 billion buyout from AstraZeneca and successfully restructured the Group into a pure biotechnology company.

Dr. Albert Fischer, Non-executive Chairman of Plant Health Care commented: "David and Jeremy have many years of board experience at public and private companies. They have an excellent understanding of the agricultural and agrichemical business domains, as well as the commercialisation of technologies through partnerships. This expertise will undoubtedly be a great asset to Plant Health Care as we continue to grow the business and create value for our shareholders."

There is no other information that is required to be disclosed pursuant to Schedule 2 paragraph (g) of the AIM Rules, save as set out below:

David Buckeridge
Current Directorships

Archimica BV
NLA FP Limited
Oxitec Limited
David Buckeridge Investigations Limited

Jeremy Scudamore
Current Directorships

ARM Holdings Plc
Boardlink Group Limited
Oxford Advanced Surfaces Limited
Oxford Advanced Surfaces Plc
Oxford Catalysts Group Plc
Skyepharma Plc

Past Directorships within last 5 years

Advanta Holdings (UK) Limited
Advanta Research Limited
Advanta Seeds UK Limited
Syngenta (AT) Limited
Syngenta (AT) Holdings Limited

Past Directorships within last 5 years

Stem Cell Sciences Plc
Chemical Industries Association Limited
Avecia Biotech Properties Limited
Avecia Fine Chemicals Limited
Avecia Finance Plc
Avecia Group Plc
Avecia Holdings Plc
Avecia 10 Limited
Avecia Corporation Limited
Avecia Limited
Avecia Pharmaceuticals Limited
Avecia Inkjet Limited
Avecia Investments Limited
Avecia Toner Resins Limited
Avecia UK Holdings Limited
AV No 2 Limited
AV No 3 Limited
Iliad 3 Limited

- ends -

For Further Information:

John Brady
Chief Executive

Tel: 001 603 525 3702

Evolution Securities Limited
Tim Worlledge/Tim Redfern

Tel: 020 7071 4300

Tavistock Communications
Jeremy Carey/Simon
Compton

Tel: 020 7920 3150